Early diagnosis of CkD and its prevention

Journal of Association of Physicians of India

Volumn 56, Issue JAN., 2008, Pages 41-46

  Amaresan, M S ^a   Geetha, R ^a  

^a Tamil Nadu Pollution Control Board   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIFESTYLE; META ANALYSIS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN INTAKE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; TIME;

AGED; CHRONIC DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIALYSIS; DIETARY PROTEINS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIFE STYLE; META-ANALYSIS AS TOPIC; MIDDLE AGED; OBESITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS;

EID: 38049136666     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Perico N, Sheppati A, Remuzzi G. Scientific Care for Prevention: an Overview. Kidney Int 2005; 67: Supp.94:S136-141.
2. Sanjay AK. Chronic Kidney Disease and its prevention. Kidney Int 2005;68:Supp.98: S41-45.
3. Wavamunno MD, David CH, Harris DC, et al. The Need for Early Nephrology referral. Kidney Int 2005;67:Supp.94:128-32.
4. Brenner BM. Retarding the Progression of renal disease. Kidney Int 2003;63:370-78.
5. Brenner BM. The history and future of renoprotection. Kidney Int 2003;64:1163-68.
6. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 Diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? Annals of Internal Medicine 2001;134:370-79.
7. Ruiz Ortega M, et al. Angiotensin II regulates the synthesis of proinflammatory cytokine and chemokines in the kidney. Kidney Int 2002;62suppl 82:S12-22.
8. Kassiske AL, Levy AS, Beck LJ. A Metaanalysis of the Effects of dietary Protein Restriction on the rate of decline in Renal Function. AJKD 1998;31:254-61.
9. Milch W, Remuzzi G. Diets for Patients with Chronic Kidney Disease still worth Prescribing. J American Society of Nephrology 2004;15:234-37.
10. Ruggenenti P, Perna Agherardi G, et al. Renoprotective properties of ACE Inhibition in Non Diabetic Nephropathies with Non Nephrotic Proteinuria. Lancet 1999;354:359-64.
11. Foley RN, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in End stage renal disease. Kidney Int 1996;49:1379-85.
12. . Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, et al. The Effect of angiotensin Converting enzyme Inhibition on Diabetic Nephropathy. The Collaborative Study Group. N Engl J of Medicine 1993;329:1456-62.
13. Wright JT. Effect of blood Pressure lowering and antihypertensive drug class on Progression of Hypertensive Kidney Disease. Results from the AASK Trial. JAMA 2002;288:2421-31.
14. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effects of the angiotensin receptor Antagonist Irbesartan in patients with nephropathy due to Type2 Diabetes. N Engl J Med 2001;345: 851-60.
15. Brenner BM, Coffee ME, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type2 Diabetes and Nephropathy. N Engl J of Medicine 2001;345: 861-69.
16. Yusuf S, Sleight P, Pogue J, et al. Effects of an Angiotensin Converting Enzyme inhibitor, Ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
17. Dahlof B, Devereux R, Siedldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study ( LIFE ). A randomized trial against Atenolol. Lancet 2002;359:995-1003.
18. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin_II receptor Blocker and angiotensin Converting Enzyme Inhibitor in Non diabetic Renal disease (COOPERATE). A Randomized Controlled Trial. Lancet 2003;361:117-24.
19. Metivier, et al. Pathophysiology of anemia and focus on the heart and blood vessels. Nephrology Dialysis and Transplant 2000;15suppl.3:14-18.
20. Vicca S, Ziad A Massy, Carole Hennequin, et al. New insights into the effects of the protein moiety of oxidized LDL (Ox-LDL). Kidney International 2003;63suppl.84:S125-27.
21. Freid LT, Orchard TJ, Kasskel, et al. Effects of Lipid reduction on the progression of Renal Disease- a Metaanalysis. Kidney International 2001;59:260-69.
22. Bagby PS. Obesity Initiated Metabolic Syndrome and the Kidney: A recipe for Chronic Kidney disease. J Am Soc Nephrol 2004;15:2775-91.
23. Orth SR. Smoking and the Kidney. J Am Soc Nephrology 2002;13:1663-72.